Lecanemab for Alzheimer’s in real life: blood markers moved first, brain swelling was rare

Responses to lecanemab emerged at 6 months, mostly in early disease, and brain swelling occurred in 7.2% of 181 people with Alzheimer’s in China, all without symptoms, in a real-world study published in October 2026 in Alzheimer’s & Dementia. It shows how this dementia drug works outside trials.

Lecanemab is an antibody that clears amyloid, a protein that builds up in the brain in Alzheimer’s disease. In clinical trials, it modestly slowed decline in early Alzheimer’s. But trials are tightly controlled, and doctors want to know how it performs in everyday practice.

What did the study do?

At several centers in Jiangsu, China, 181 people with Alzheimer’s received lecanemab every two weeks. Researchers measured whether each person had a meaningful change on a standard dementia rating at months 3, 6 and 12, and tracked blood biomarkers: p-tau217 and the amyloid ratio Aβ42/40.

What did the study find about dementia?

• Signs of response appeared at month 6 and grew stronger by month 12.
• Response was mostly limited to people with mild cognitive impairment or mild dementia due to Alzheimer’s.
• People who carried the APOE ε4 gene variant or had more severe impairment were less likely to respond.
• Blood biomarkers changed as early as month 3, before clinical improvement.
• Brain swelling or small bleeds seen on MRI, called ARIA, occurred in 7.2%, and none had symptoms.

Why does this matter?

Real-world results help doctors decide who is most likely to benefit. This study supports treating early, and suggests a blood test at 3 months might one day help track whether treatment is working.

How solid is this evidence?

It’s moderate. Mongevity rates it C on our A-to-E scale: a multicenter real-world study, but with no comparison group, a modest number of patients and exploratory biomarker analyses. The authors’ statement that lecanemab is effective can’t be confirmed without a control group.

What are the open questions?

Whether early blood marker changes truly predict who benefits needs testing in larger studies. Longer follow-up is also needed, both for benefit and for safety, since ARIA can sometimes cause symptoms.

What does this mean for you?

If you notice memory changes in yourself or a relative, see a doctor early: treatments like lecanemab are meant for the earliest stages. If you’re considering it, ask about APOE testing, MRI monitoring and how often infusions are needed.

How do I explain this at dinner?

A new Alzheimer’s drug that clears a sticky brain protein was tried in everyday clinics in China. Blood tests changed within three months, and benefits showed up later, mostly in people treated early. A good question for the table: why might timing matter so much with Alzheimer’s?

In one sentence: in real-world use in China, lecanemab showed responses from 6 months, mostly in early Alzheimer’s, with early blood marker changes and uncommon, symptom-free brain swelling.